Ilboudo Patrick G, Huang Xiao Xian, Ngwira Bagrey, Mwanyungwe Abel, Mogasale Vittal, Mengel Martin A, Cavailler Philippe, Gessner Bradford D, Le Gargasson Jean-Bernard
Agence de Médecine Préventive, Abidjan, Côte d'Ivoire.
Agence de Médecine Préventive, Ferney-Voltaire, France.
PLoS One. 2017 Sep 21;12(9):e0185041. doi: 10.1371/journal.pone.0185041. eCollection 2017.
Cholera remains an important public health problem in many low- and middle-income countries. Vaccination has been recommended as a possible intervention for the prevention and control of cholera. Evidence, especially data on disease burden, cost-of-illness, delivery costs and cost-effectiveness to support a wider use of vaccine is still weak. This study aims at estimating the cost-of-illness of cholera to households and health facilities in Machinga and Zomba Districts, Malawi. A cross-sectional study using retrospectively collected cost data was undertaken in this investigation. One hundred patients were purposefully selected for the assessment of the household cost-of-illness and four cholera treatment centres and one health facility were selected for the assessment conducted in health facilities. Data collected for the assessment in households included direct and indirect costs borne by cholera patients and their families while only direct costs were considered for the assessment conducted in health facilities. Whenever possible, descriptive and regression analysis were used to assess difference in mean costs between groups of patients. The average costs to patients' households and health facilities for treating an episode of cholera amounted to US$65.6 and US$59.7 in 2016 for households and health facilities, respectively equivalent to international dollars (I$) 249.9 and 227.5 the same year. Costs incurred in treating a cholera episode were proportional to duration of hospital stay. Moreover, 52% of households used coping strategies to compensate for direct and indirect costs imposed by the disease. Both households and health facilities could avert significant treatment expenditures through a broader use of pre-emptive cholera vaccination. These findings have direct policy implications regarding priority investments for the prevention and control of cholera.
在许多低收入和中等收入国家,霍乱仍然是一个重要的公共卫生问题。疫苗接种已被推荐为预防和控制霍乱的一种可能干预措施。然而,支持更广泛使用疫苗的证据,尤其是关于疾病负担、疾病成本、交付成本和成本效益的数据仍然不足。本研究旨在估计马拉维马钦加和宗巴地区霍乱对家庭和卫生设施造成的疾病成本。本调查采用回顾性收集成本数据的横断面研究。本研究特意选取了100名患者来评估家庭疾病成本,并选取了四个霍乱治疗中心和一个卫生设施来评估卫生设施的疾病成本。家庭评估收集的数据包括霍乱患者及其家庭承担的直接和间接成本,而卫生设施评估仅考虑直接成本。只要有可能,就使用描述性分析和回归分析来评估患者组之间平均成本的差异。2016年,患者家庭和卫生设施治疗一次霍乱的平均成本分别为65.6美元和59.7美元,同年分别相当于国际美元(I$)249.9和227.5。治疗霍乱发作的成本与住院时间成正比。此外,52%的家庭采用应对策略来弥补疾病带来的直接和间接成本。通过更广泛地使用预防性霍乱疫苗接种,家庭和卫生设施都可以避免大量的治疗支出。这些发现对于霍乱预防和控制的优先投资具有直接的政策意义。